DYAX Profile
Dyax Corp. (DYAX) was a biopharmaceutical company that focused on developing treatments for rare diseases. The company was founded in 1989 and was headquartered in Burlington, Massachusetts.
Dyax was best known for developing KALBITOR, a treatment for hereditary angioedema (HAE), a rare genetic disorder that causes episodes of severe swelling in various parts of the body. KALBITOR was approved by the U.S. Food and Drug Administration in 2009 and was considered a breakthrough treatment for HAE.
In 2016, Dyax was acquired by Shire plc, a global biopharmaceutical company that specializes in developing treatments for rare diseases. The acquisition was aimed at strengthening Shire's position in the HAE market and expanding its product portfolio.
As a result of the acquisition, Dyax Corp. is no longer a publicly traded company. However, its legacy continues through its contributions to the development of treatments for rare diseases, particularly HAE. The acquisition also provided Dyax shareholders with a premium on their investment, and the opportunity to participate in the growth of Shire plc as a leading provider of treatments for rare diseases.
|
